Investor Presentaiton
Commitment to Research and Development
R&D Spend
US$m
900
832
750
702
667
614
600
466
463
450
300
150
0
FY14
FY15 FY16 FY17
FY18
FY19
New Product Development
activities focus on innovative new therapies for life-threatening diseases
Market Development
strategies seek to bring therapies to new markets and new indications
Life Cycle Management
ensures continuous improvement of existing products
New R&D Facilities
Bio21 Institute, Melbourne
~ 4100m² of lab and office space
Parkville precinct
•
•
•
Melbourne University, MRI's
4 major teaching hospitals
SITEM1, Bern
• 2000m² of lab and office space
Bern University and Hospital campus
Gene therapy, Pasadena
•
•
•
Expanding gene therapy expertise
Research, QA, cell processing and
manufacture
Wet-lab space (non-GMP) tripled from
132 to 480 m²
GMP space (330 m²) to engineering
qualification level
1. SITEM - Swiss Institute for Translational and Entrepreneurial Medicine.
14 Driven by Our Promise™
CSLView entire presentation